Le Lézard
Classified in: Science and technology
Subject: PDT

LIFARS Introduces Cyber Vaccine in the Battle Against Ransomware Attacks

NEW YORK, Dec. 6, 2019 /PRNewswire/ -- LIFARS, the global leader in cyber incident response, digital forensics, and security services announced the release of Cyber Vaccine, a new weapon against one of the most prolific organized crime phenomena of the 21st century ? ransomware attacks. Cyber Vaccine was crafted specifically for the Dridex malware strain, commonly used by the large-scale ransomware campaigns known as BitPaymer and DoppelPaymer.


These campaigns have collected millions of dollars in recent years, crippling large, mid, and even small sized companies across the globe. As businesses try to adjust to this new threat and address the fears of clients and stakeholders, one thing remains clear ? the threat is real. There is no quick, easy or cheap way out once your organization is hit... or is there? Queue Cyber Vaccine.

A major leverage for receiving a ransom payment is the victim's alternative arduous and costly undertaking of rebuilding an infected business infrastructure.  During clean up and rebuild, customers and stakeholders grow agitated because of the business impact caused by the work-stoppage.  Where normally the recovery takes days, weeks, or months, recovery with Cyber Vaccine could potentially happen overnight. And, it just requires one IT member who knows how to administer it.  "Something we've seen over and over during incident response cases is a detrimentally lean IT team. Understaffing makes day-to-day cyber hygiene nearly impossible, let alone a full network rebuild after a ransomware attack," explains LIFARS IR Project Manager.

That common scenario makes Cyber Vaccine even more critical to recovery efforts.  It is fast-acting and thorough, allowing even understaffed IT teams to recover without a full wipe and rebuild of all the infected systems. "It takes a virus to kill a virus," explains LIFARS CEO Ondrej Krehel, "Cyber Vaccine is the new offensive measure in malware eradication."

When asked why LIFARS is offering Cyber Vaccine as open source, the malware researcher who created it, dubbed mwlac, explains "It is important that we all work together to fight these criminal groups. The less threat intelligence we share, the worse off we all are and the more money the criminals make."

The technical write-up for Cyber Vaccine is available online at https://lifars.com/2019/11/analysis-of-dridex-bitpaymer-and-doppelpaymer-campaign/

Cyber Vaccine's open source code, created by LIFARS, is available on GitHub: https://github.com/Lifars/Dridex-Vaccine

For more info: info@lifars.com or +1 (212) 222-7061 and www.LIFARS.com


These press releases may also interest you

at 20:10
FINEOS Corporation , the global market leader in core systems for life, accident and health insurance, has entered into an agreement to acquire Limelight Health, a leading North American provider of quoting, rating and underwriting solutions for...

at 19:54
Extreme Networks, Inc. , a cloud-driven networking company, today announced its upcoming conference schedule for August and September:...

at 19:25
The Arizona Bioindustry Association (AZBio) today announced the lineup for the fifth annual Arizona Bioscience Week including its schedule of daily online community educational programs, a 1-hour television special Celebrating Life & Science, and the...

at 19:18
GPX Global Systems Inc., the premier provider of carrier-neutral Edge data center services in Africa and South Asia, today announced the sale of its Indian operations to Equinix, Inc. , the all-cash transaction value of US$161 million is expected to...

at 19:05
GlobalPlatform, the standard for secure digital services and devices, and Winbond will host a free-to-attend ?IoT Security and Certification Schemes' workshop on Tuesday, August 25 at the Sheraton Hsinchu Hotel in Zhubei City, Taiwan. The event is...

at 19:01
The Trendlines Group Ltd. (the "Company" and together with its subsidiaries, "Trendlines" or the "Group") (SGX: 42T) and , an Israel- and Singapore-based investment group focused on inventing technologies and creating medical device...

News published on 6 december 2019 at 16:38 and distributed by: